News
Dyadic to release second quarter 2024 financial results on Tuesday, August 13, 2024
Dyadic International, Inc.
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,” “we,” “our” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale manufacturing of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition and wellness, today announced that it will report its financial results for the second quarter of 2024 and host a corporate update conference call on Tuesday, August 13, 2024.
Conference Call Information:
Date: Tuesday, August 13, 2024
Time: 5:00 PM Eastern Time
Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560
Conference ID: 13743569
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1650832&tp_key=276447f116. An archive of the webcast will be available within 24 hours after the conclusion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.dyadic.com. To access the webcast replay, please follow the webcast link above.
If you have any questions you would like to ask management during the Q&A session, please email ir@dyadic.com before the conference call.
About Dyadic International, Inc.
Dyadic International, Inc. is a biotechnology company focused on the efficient, large-scale manufacturing of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition and wellness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our leading technology, the C1 cell protein production platform, is based on an industrially proven microorganism (called C1) that is currently used to accelerate the development, reduce production costs and improve the performance of vaccines and biologics at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungus-based microbial protein production platform to enable rapid development and large-scale manufacturing of low-cost proteins, metabolites and other biologics for use in non-pharmaceutical applications such as food, nutrition and wellness.
With a passion to enable our partners and collaborators to develop effective preventive and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline advancing its proprietary microbial platform technologies, including biologic vaccines, antibodies and other biologics.
The story continues
To learn more about Dyadic and our commitment to helping bring vaccines and other biologics to market faster, in greater volumes and at lower cost, visit https://www.dyadic.com.
Safe Harbor About Looking to the future Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those related to Dyadic International’s expectations, intentions, strategies and beliefs concerning future events or future financial performance, such as the issuance of Convertible Notes and the use of proceeds therefrom. Actual events or results may differ materially from those in the forward-looking statements due to a number of important factors, including those described in the Company’s most recent filings with the SEC. Dyadic undertakes no obligation to publicly update any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ materially from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which can be accessed on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
CFO
Phone: (561) 743-8333
Email: ir@dyadic.com